Skip to main content
. 2016 May 3;9:257. doi: 10.1186/s13071-016-1518-1

Fig. 6.

Fig. 6

Evaluation of ICT based on rBcMSA1 and rBcSA1. a Cross-reactivity of ICT using rBcMSA1 with closely related parasite-infected canine sera: lane 1, B. rossi-infected dog serum; lane 2, B. vogeli-infected dog serum; lane 3, B. gibsoni-infected dog serum; lane 4, L. infantum-infected dog serum; lane 5, B. canis-infected dog serum; lane 6, a SPF dog serum; b Specific antibody responses to rBcMSA1 in sequential serum samples from a non-splenectomized dog experimentally infected with B. canis; c Cross-reactivity of rBcSA1 with closely related parasite-infected canine sera: lane 1, SPF dog serum; lane 2, B. canis-infected dog serum; lane 3, B. rossi-infected dog serum; lane 4, B. vogeli-infected dog serum; lane 5, B. gibsoni-infected dog serum; lane 6, L. infantum-infected dog serum; d Specific antibody responses to rBcSA1 in sequential serum samples from a non-splenectomized dog experimentally infected with B. canis